与领导相处的艺术
OP0025?Results from a multicenter, international, randomized, double-blind, placebo-controlled, pha 2 study of sirukumab, a human anti-IL-6
monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy 期刊名称： Annals of the Rheumatic Dias
作者： Hsu, B.,Sheng, S.,Weinblatt, M.E.,Smolen, J.S.光棍节 英文>minimum是什么意思
amnesty>opposite是什么意思srtp>hkma年份： 2013年
期号： 第Suppl 3期风景区英文
摘要：Objectives To asss remission rates from a pha 2 study of sirukumab, a human monoclonal antibody against the cytokine interleukin-6 (formerly named CNTO 136), using the new provisional 2011 ACR/EULAR rheumatoid arthritis (RA) remission criteria. Methods In the do-ranging part of a 2-part, multicenter, randomized, double blind, placebo controlled, pha 2 study, pts with active RA despite methotrexate (MTX) were randomized equally to receive SC injections of placebo q2w at wks 0-
10 and sirukumab 100 mg q2w at wks 12-24 (n=30), sirukumab 100 mg q2w at wks 0-24 (n=30), sirukumab 100 mg q4w at wks 0-24 (n=30), sirukumab 50 mg q4w at wks 0-24 (n=30), or sirukumab 25 mg q4w at wks 0-24
foxhole(n=31). RA remission rates were prospectively assd using the DAS28 (CRP) remission criteria and retrospectively assd using the 2011
公主与青蛙内容由中国教育图书进出口有限公司引进
